These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12830932)

  • 1. New developments in the pharmacotherapy of schizophrenia.
    Fleischhacker WW
    J Neural Transm Suppl; 2003; (64):105-17. PubMed ID: 12830932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polypharmacy in schizophrenia.
    Zink M; Englisch S; Meyer-Lindenberg A
    Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.
    Citrome L
    Expert Rev Neurother; 2013 Jul; 13(7):767-83. PubMed ID: 23898849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
    Schulz C; Timm J; Cordes J; Gründer G; Mühlbauer B; Rüther E; Heinze M
    Clin Trials; 2016 Jun; 13(3):251-9. PubMed ID: 27016729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
    Kelleher JP; Centorrino F; Albert MJ; Baldessarini RJ
    CNS Drugs; 2002; 16(4):249-61. PubMed ID: 11945108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
    Masand PS; Gupta S
    Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
    Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
    Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Polypharmacy in schizophrenia].
    Zink M; Englisch S; Meyer-Lindenberg A
    Nervenarzt; 2011 Jul; 82(7):853-8. PubMed ID: 21165589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
    Sebastian CS; Glazer W; Buckley PF
    Curr Med Chem; 2004 Feb; 11(3):329-42. PubMed ID: 14965235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
    Simon N; Azorin JM
    Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of schizophrenia: ploypharmacy approaches.
    Rahiminejad F; Akhondzadeh S
    Acta Med Iran; 2010; 48(4):203-8. PubMed ID: 21279929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G; Chong SA
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psychopharmocotherapy of schizophrenia in forensic and general psychiatry].
    Stompe T; Schanda H
    Neuropsychiatr; 2011; 25(2):75-84. PubMed ID: 21672506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.